$LLY

Zakrowski Donald A sold $2.4M of LLY

Zakrowski Donald A (SVP, Finance, & CAO) sold 2,000 shares of ELI LILLY & Co (LLY) at $1185.01 ($2.37M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zakrowski Donald A
Published Aug 11, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational, financial, or regulatory information about LLY.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it less actionable as a fundamental signal.

03

What to watch

The sale size ($2.37M) and remaining holdings (1,526 shares) matter for context, but the article provides no trend history or whether other insiders sold around the same time.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows LLY SVP, Finance and CAO Donald Zakrowski sold 2,000 shares on 2026-08-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact on LLY price; any effect is more sentiment-related than fundamental.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through; this is company-specific insider dealing without new sector catalysts.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can still reflect personal liquidity needs or risk management, but it is not strong enough to infer deteriorating fundamentals from a single transaction.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider transaction disclosure.

  • Donald Zakrowski

    SVP, Finance and CAO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYLowAI 8/10

FDA approval for Lilly’s weekly insulin Onswik, shares dip

The FDA approved Eli Lilly's (LLY) once-weekly insulin Onswik for type 2 diabetes. The drug, already approved in the EU, Mexico, and Japan, aims to reduce injections from 365 to 52 per year. Despite the approval, LLY shares dipped 1.6%. Lilly's revenue and net income have surged, reaching $22.97bn and $7.1bn respectively in Q2 2026. The company faces competition from Novo Nordisk's Awiqli in the weekly insulin market.

$LLYHighAI 9/10

New once-weekly insulin injection for type 2 diabetes wins FDA approval

Eli Lilly's once-weekly insulin, Onswik, received FDA approval for type 2 diabetes. It reduces annual injections by over 300 compared to daily insulin. Trials with 3,400+ adults showed A1C declines similar to daily insulin glargine. Onswik will be available in the US in pre-filled pens. According to Lilly, it offers an alternative to daily injections.